Nortriptyline is NOT Recommended for Insomnia Treatment
Nortriptyline should not be used for treating insomnia. Major clinical practice guidelines explicitly exclude nortriptyline from recommended insomnia treatments, and there is insufficient evidence supporting its efficacy or safety for this indication 1.
Why Nortriptyline is Inappropriate for Insomnia
Guideline Recommendations Are Clear
The 2017 American Academy of Sleep Medicine (AASM) clinical practice guideline systematically evaluated pharmacologic treatments for chronic insomnia and did not include nortriptyline among the 14 agents reviewed 1. The guideline only recommended:
- Doxepin (3-6 mg) as the sole antidepressant with a weak recommendation for sleep maintenance insomnia 1
- Trazodone received a negative recommendation (clinicians should NOT use it) 1
The 2016 American College of Physicians evidence report found that evidence for antidepressants in general populations was insufficient or of low strength 2. The 2023 European Insomnia Guideline recommends "low-dose sedating antidepressants" only as a weak recommendation for short-term use (≤4 weeks) when cognitive-behavioral therapy fails 3.
FDA Labeling Does Not Support This Use
The FDA label for nortriptyline makes no mention of insomnia as an indication 4. In fact, the label lists insomnia as a potential adverse effect and warns about:
- Increased suicidality risk, especially during initial treatment 4
- Cardiovascular risks including tachycardia, arrhythmias, myocardial infarction, and stroke 4
- Anticholinergic effects that are particularly problematic in elderly patients 4
- Not recommended for pediatric patients 4
Dosing Would Be Inappropriate
Nortriptyline's FDA-approved dosing is 25 mg 3-4 times daily (75-100 mg/day total) for depression 4, which is far higher than the low doses used for other sedating antidepressants in insomnia (e.g., doxepin 3-6 mg). The therapeutic plasma concentration range for depression is 50-150 ng/mL 4, but there is no established therapeutic range for insomnia.
What to Use Instead
First-Line Treatment
Cognitive-behavioral therapy for insomnia (CBT-I) is the first-line treatment for chronic insomnia in adults of any age, including those with comorbidities 3. This can be delivered in-person or digitally.
When Pharmacotherapy is Needed
If CBT-I is insufficient or unavailable, consider these evidence-based options:
For sleep maintenance insomnia:
- Doxepin 3-6 mg (the only antidepressant with guideline support) 1
- Suvorexant (orexin receptor antagonist) 1
- Eszopiclone or zolpidem 1
For sleep onset insomnia:
Duration considerations:
- Benzodiazepines and benzodiazepine receptor agonists: ≤4 weeks 3
- Orexin receptor antagonists: up to 3 months or longer in selected cases 3
- Prolonged-release melatonin: up to 3 months in patients ≥55 years 3
Critical Safety Considerations
The limited research on nortriptyline and sleep comes from studies in depressed patients, not primary insomnia 5. While one study showed nortriptyline reduced REM sleep and sleep apnea in elderly depressed patients 5, this does not translate to a recommendation for insomnia treatment. The cardiovascular and anticholinergic risks, combined with lack of efficacy data, make nortriptyline a poor choice.
Recent evidence on low-dose tricyclic antidepressants (amitriptyline 10-20 mg) showed only modest short-term benefit that was not sustained beyond 6 weeks 6, further undermining the rationale for using nortriptyline at any dose for insomnia.